Galectin Therapeutics Inc.

Contributing Author

Recent Articles by Galectin Therapeutics Inc.

Nov-05	Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026 GALT -13.98% GlobeNewswire
Oct-06	Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 GALT GlobeNewswire
Sep-10	Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference GALT GlobeNewswire
Aug-14	Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update GALT GlobeNewswire
Aug-04	Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet GALT GlobeNewswire
Jun-23	Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension GALT +11.43% GlobeNewswire
May-27	Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis GALT GlobeNewswire
May-15	Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update GALT -7.66% GlobeNewswire
May-11	Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology GALT +5.24% GlobeNewswire
Mar-31	Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update GALT +8.56% GlobeNewswire
Mar-17	Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. GALT GlobeNewswire
Feb-26	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET GALT GALT -5.10% GlobeNewswire
Dec-19	Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 GALT -28.90% GlobeNewswire
Nov-14	Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update GALT GlobeNewswire
Nov-10	Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting GALT GlobeNewswire
Oct-20	Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference GALT GlobeNewswire
Oct-07	Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 GALT +7.43% GlobeNewswire
Sep-02	Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference GALT GlobeNewswire
Aug-14	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update GALT GlobeNewswire
Jul-09	Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 GALT +7.66% GlobeNewswire
Jun-10	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension GALT GlobeNewswire
May-15	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update GALT GlobeNewswire
May-12	Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress GALT GlobeNewswire

Galectin Therapeutics Inc.

Recent Articles by Galectin Therapeutics Inc.

Upgrade your Finviz experience